Biogen Inc. (BIIB) Stake Maintained by Plancorp LLC

Plancorp LLC held its position in shares of Biogen Inc. (NASDAQ:BIIB) during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 2,765 shares of the biotechnology company’s stock at the end of the first quarter. Plancorp LLC’s holdings in Biogen were worth $756,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the stock. Crestwood Advisors Group LLC bought a new position in shares of Biogen during the first quarter valued at $106,000. Winfield Associates Inc. increased its stake in shares of Biogen by 16.8% in the first quarter. Winfield Associates Inc. now owns 467 shares of the biotechnology company’s stock valued at $128,000 after buying an additional 67 shares during the period. Rational Advisors LLC increased its stake in shares of Biogen by 14.3% in the first quarter. Rational Advisors LLC now owns 593 shares of the biotechnology company’s stock valued at $162,000 after buying an additional 74 shares during the period. Stelac Advisory Services LLC purchased a new stake in shares of Biogen during the first quarter valued at about $164,000. Finally, Cohen Capital Management Inc. purchased a new stake in shares of Biogen during the first quarter valued at about $178,000. Institutional investors own 87.47% of the company’s stock.

Biogen Inc. (BIIB) opened at 282.92 on Friday. The company has a 50-day moving average of $269.15 and a 200-day moving average of $273.86. The company has a market capitalization of $60.01 billion, a PE ratio of 17.72 and a beta of 0.78. Biogen Inc. has a 52 week low of $244.28 and a 52 week high of $307.76.

Biogen (NASDAQ:BIIB) last posted its earnings results on Tuesday, April 25th. The biotechnology company reported $5.20 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $4.97 by $0.23. Biogen had a net margin of 30.17% and a return on equity of 38.17%. The business had revenue of $2.81 billion for the quarter, compared to analysts’ expectations of $2.73 billion. During the same period in the prior year, the company posted $4.79 EPS. The business’s revenue for the quarter was up 3.1% compared to the same quarter last year. On average, equities research analysts anticipate that Biogen Inc. will post $20.44 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by [[site]] and is the property of of [[site]]. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at [[permalink]].

BIIB has been the subject of several recent analyst reports. Leerink Swann set a $300.00 target price on shares of Biogen and gave the company a “hold” rating in a research note on Monday, April 3rd. Vetr upgraded shares of Biogen from a “buy” rating to a “strong-buy” rating and set a $311.67 target price for the company in a research note on Tuesday, June 27th. Deutsche Bank AG initiated coverage on shares of Biogen in a research note on Friday, June 23rd. They issued a “buy” rating and a $315.00 target price for the company. Cowen and Company reiterated a “buy” rating and issued a $338.00 target price on shares of Biogen in a research note on Tuesday, April 25th. Finally, Barclays PLC reiterated an “overweight” rating and issued a $360.00 target price (down from $380.00) on shares of Biogen in a research note on Sunday, April 23rd. Thirteen equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and two have given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $325.48.

In other Biogen news, VP Paul J. Clancy sold 9,892 shares of the stock in a transaction that occurred on Tuesday, April 25th. The shares were sold at an average price of $290.00, for a total value of $2,868,680.00. Following the sale, the vice president now directly owns 10,813 shares in the company, valued at approximately $3,135,770. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Susan H. Alexander sold 7,758 shares of the stock in a transaction that occurred on Wednesday, July 19th. The stock was sold at an average price of $285.00, for a total transaction of $2,211,030.00. Following the completion of the sale, the executive vice president now owns 27,232 shares in the company, valued at $7,761,120. The disclosure for this sale can be found here. Insiders sold a total of 18,734 shares of company stock worth $5,357,550 over the last quarter. Corporate insiders own 0.32% of the company’s stock.

Biogen Company Profile

Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).

Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB).